Get started
Author

Philippe Legenne

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
2016 · Georgina V Long, Jean-Jacques Grob, et al. · The Lancet Oncology · 324
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease
2012 · Kevin Harrington, Alain Berrier, et al. · European Journal of Cancer · 122
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
2015 · Kevin Harrington, Stephane Temam, et al. · Journal of Clinical Oncology · 106
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group, Angela J. Rogers, et al. · Annals of Internal Medicine · 60
PDF
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
2020 · Victoria Atkinson, Shahneen Sandhu, et al. · Melanoma Research · 39
Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study
2013 · David R. Spigel, David M. Waterhouse, et al. · Clinical Lung Cancer · 34
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19: A Randomized Controlled Trial
2022 · ACTIV-3/TICO Study Group*, Christina Barkauskas, et al. · Annals of Internal Medicine · 33
PDF
Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).
2010 · K. J. Harrington, A. Berrier, et al. · Journal of Clinical Oncology · 26
Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).
2014 · Kevin J. Harrington, Stéphane Temam, et al. · Journal of Clinical Oncology · 25
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
2015 · B Milojkovic Kerklaan, M P J Lolkema, et al. · British Journal of Cancer · 24
PDF
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19
2024 · Neil R Aggarwal, Jacquie Nordwall, et al. · Clinical Infectious Diseases · 17
PDF
Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program
2019 · Salvador Martin-Algarra, Rebecca Hinshelwood, et al. · Melanoma Research · 12
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
2026 · Neeltje Steeghs, Carlos Gomez-Roca, et al. · Nature Cancer · 10
PDF
MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
2024 · Mojca Jongen-Lavrencic, Thomas Pabst, et al. · Blood · 10
PDF
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
2024 · Stefan Knop, Monika Szarejko, et al. · eJHaem · 10
PDF
Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.
2016 · Jean Jacques Grob, Keith Flaherty, et al. · Journal of Clinical Oncology · 9
Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.
2024 · Neeltje Steeghs, Carlos A. Gomez-Roca, et al. · Journal of Clinical Oncology · 8
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
2022 · Stefanie Fischer, Thorsten O. Götze, et al. · JCO Precision Oncology · 7
Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors.
2013 · Bojana Milojkovic Kerklaan, Martijn P. J. K. Lolkema, et al. · Journal of Clinical Oncology · 7
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer
2010 · Peter G. Rose, Bradley J. Monk, et al. · Gynecologic Oncology · 7
Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study
2023 · Nina Stojcheva, Stacy Gladman, et al. · British Journal of Clinical Pharmacology · 6
PDF
Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study.
2013 · Rodryg Ramlau, Jacek Jassem, et al. · Journal of Clinical Oncology · 6
MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study
2023 · Thomas Pabst, Mojca Jongen-Lavrencic, et al. · Blood · 5
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
2023 · Carlos A. Gomez-Roca, Neeltje Steeghs, et al. · Journal of Clinical Oncology · 5
A Decade of Clinical Experience with DARPins in Oncology and Virology: A Systematic Review
2025 · Michael T. Stumpp, Vladimir Kirkin, et al. · medRxiv · 4
PDF
Works count: 45
Citation count: 976
H-index: 12
I10-index: 16
Year
Topic
Type